EMA Veterinary Innovation Day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 March 2025, 13:30 (CET) to 14 March 2025, 12:30 (CET)

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0062/2024

EMEA-003225-PIP01-22

EMEA-003425-PIP01-23

EMEA-003519-PIP01-23

EMEA-003520-PIP01-23

EMEA-003541-PIP01-23

Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Date of authorisation: 20/11/2018, Revision: 10, Status: Authorised

Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 March 2025, 11:00 (CET) to 6 March 2025, 11:30 (CET)

Orphan designation: Octreotide acetate Treatment of acromegaly, 05/08/2013 Withdrawn